Introduction {#sec1}
============

The pregnane X receptor (*PXR*), also referred to as nuclear receptor subfamily 1 group I member 2 (*NR1I2*) and steroid and xenobiotic receptor (*SXR*), is a ligand-dependent transcription factor belonging to the orphan nuclear receptors superfamily \[[@B1]\] and plays an essential role in adaptive defense system against endogenous metabolites and toxic xenobiotics \[[@B4]\]. The discovery of the *PXR* supplied novel perspectives on the molecular basis of the drug resistance in cancer cells \[[@B5]\]. What is more, *PXR* also participates in regulating the proliferation of either cancer or non-cancer cells. In cancer cells, it can control cell growth in various cancer tissues such as ovarian, prostate, colon, endometrial, breast, and so on \[[@B6]\]. Strong associations have been revealed between *PXR* and the proliferation of cancer \[[@B1],[@B4],[@B11]\].

The *PXR* gene is located on chromosome 3q12-13.33, spanning 35 kb with ten exons and nine introns. Its coding protein contains a ligand-dependent transactivation function 2, a ligand-binding domain, a hinge region, and a DNA-binding domain \[[@B12]\]. Numerous single nucleotide polymorphisms (SNPs) have been observed in *PXR* gene and the putatively functional SNPs may influence its expression or function. Currently, accumulating studies have yet investigated the associations between SNPs of *PXR* and the cancer susceptibility, however, the findings were conflicting. For instance, the rs3814057 polymorphism was related to an elevated cancer risk in our meta-analysis, while it showed no association in Christina Justenhoven's study \[[@B13]\]. Additionally, no systematic review containing all tested SNPs of *PXR* has been published yet.

We aim to fill this blank by performing a systematic review and meta-analysis of the available evidence, explore the correlation of *PXR* SNPs with cancer susceptibility, and provide clues for researchers to design future studies and screen novel functional genetic biomarkers for cancer prediction.

Materials and methods {#sec2}
=====================

Retrieval strategy {#sec2-1}
------------------

A comprehensive literature search was performed independently by two investigators (J.W. and Z.L.) to find all publications regarding the correlation between the *PXR* polymorphisms and cancer risk. We retrieved the PubMed and Web of Science database by using the following query terms: '(*PXR* or pregnane X receptor or *NR1I2* or nuclear receptor 1I2 or nuclear receptor subfamily 1 group I member 2 or or *SXR* or steroid X receptor or 'steroid and xenobiotic receptor') and (polymorphism or SNP or variant or variation) and (cancer or tumor or carcinoma or neoplasm)', up to 16 November 2017.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The following inclusion criteria were adopted to identify all eligible publications: (i) a case--control-designed study; (ii) about the association between *PXR* SNPs and cancer risk. The main exclusion criteria were: (i) duplicate studies; (ii) unrelated to cancer or *PXR* SNPs; (iii) not sufficient data.

Data extraction {#sec2-3}
---------------

Data extraction was independently completed by two of the investigators (J.W. and Z.L.). Items obtained from each eligible publication included: first author, year of publication (unpublished showed study year), country of origin, cancer type, SNP locus, sample size, genotype counts in cases and controls, Hardy--Weinberg equilibrium (HWE) in controls, source of control groups, genotyping method, and adjusted factors. If an article contained multiple study populations or sources, data were extracted respectively. If data were unreported in eligible articles, we spared no effort to contact the corresponding authors.

Methodology quality assessment {#sec2-4}
------------------------------

The quality evaluation of the selected studies was scored by two reviewers (J.W. and H.D.) independently, according to a study on assigning quality scores which was mentioned in a previous meta-analysis \[[@B14]\]. A third investigator (X.F.) would be involved when disagreement existed. Six items were evaluated: (i) representativeness of the cases; (ii) source of the controls; (iii) ascertainment of relevant cancers; (iv) sample size; (v) quality control of the genotyping methods; (vi) HWE. The scores for quality assessment ranged from 0 to 10 and studies with less than 5 score were not involved in the subsequent analysis.

Trial sequential analysis {#sec2-5}
-------------------------

The results of meta-analysis can be misled by random errors (play of chance) or systematic errors (bias) due to sparse data and/or repeated significance testing. Therefore, a trial sequential analysis tool (TSA from Copenhagen Trial Unit, Center for Clinical Intervention Research, Denmark, 2011) was conducted in our meta-analysis to gain more reliable findings \[[@B15]\]. In brief, TSA evaluates the required information size by setting type-I error of 5%, type-II error of 20%, and statistical test power of 80%, and then plots a two-sided graph, where TSA monitoring boundaries (red lines) were built \[[@B16]\]. If the TSA monitoring boundaries were crossed with Z-curve (blue lines) before reaching the required information size, robust conclusion might have been identified and further studies are unnecessary \[[@B16]\]. Otherwise, more trials are still in demand.

False-positive report probability {#sec2-6}
---------------------------------

We evaluated the significant findings by computing false-positive report probability (FPRP), which was based on observed *P*-value, statistical power of test, and prior probability \[[@B17]\]. To identify a significant association as 'noteworthy', prior probabilities of 0.25, 0.01, 0.001, 0.0001 were assigned and 0.2 was set as FPRP cut-off value \[[@B18]\].

Statistical analysis {#sec2-7}
--------------------

All the statistical analyses in the present study were performed by STATA software, version 11.0 (STATA Corp., College Station, TX, U.S.A.). All tests were two-sided and *P*-value \<0.05 was considered as a statistical significance level unless we highlighted once more. The dominant genetic model was defined as homozygote + heterozygote variant compared with homozygote wild, while the recessive genetic model was defined as homozygote variant compared with homozygote + heterozygote wild. The HWE for the genotype distributions of *PXR* SNPs in controls was calculated by chi-square test, and *P*-values \<0.05 was considered as significant disequilibrium. The intensity of the relations between the *PXR* SNPs and cancer risk was evaluated by pooled odds ratios (ORs) and 95% confidence intervals (95%CIs), calculated by fixed effect model \[[@B19]\] when the between-study heterogeneity was absent, otherwise random effect models \[[@B20]\]. The between-study heterogeneity was calculated by Cochran's *Q*-test (significance at *I^2^*\> 50%). Begg's test, a funnel plot analysis and Egger's linear regression analysis were conducted to calculate the publication bias. *P*-value \<0.10 was considered as statistically significant in both Begg's or Egger's test. What is more, sensitivity analyses were performed to inspect whether the summary findings were robust after excluding one or two outlying studies.

Results {#sec3}
=======

Characteristics of the eligible studies {#sec3-1}
---------------------------------------

According to the selection process showed in [Figure 1](#F1){ref-type="fig"}, total 102 publications were collected through database searching. Ninety-five records were excluded after reading titles and abstracts (38 were functional studies; 11 were reviews; 2 were not case--control studies; 7 were not related to *PXR* SNPs; 14 were not correlated with cancer; 23 were not associated with cancer risks). Hence, total eight case--control studies (from seven citations) covering 11143 cases and 12170 controls were involved in our meta-analyses, which met the inclusion criteria and the quality assessment. Moreover, the genotype distributions of all records were in agreement with HWE (*P*~HWE~\>0.05). The characteristics of these included articles were shown in [Table 1](#T1){ref-type="table"} and the distributions of *PXR* SNPs genotype frequency were reported in [Table 2](#T2){ref-type="table"}.

![The flow chart of identification for studies included in the meta-analysis](bsr-38-bsr20171614-g1){#F1}

###### The main features of enrolled studies

  Ref. No.   Year   Country              Ethnicity   Sample size   Source of controls   Genotyping method   Adjusted factors                       Quality score                                                                           Citation   
  ---------- ------ -------------------- ----------- ------------- -------------------- ------------------- -------------------------------------- --------------------------------------------------------------------------------------- ---------- ------------
  1          2008   China/Malay/Indian   Asian       62            300                  PB                  Applied Biosystems 3730 DNA Analyzer   NM                                                                                      7          \[[@B5]\]
  2          2010   Germany              Asian       2984          5318                 PB                  MALDI-TOF MS                           Age, study region, family history of breast cancer, and BMI                             10         \[[@B21]\]
  3          2011   Germany              Caucasian   1020          1014                 PB                  MALDI-TOF MS                           Age, menopausal status, family history of breast cancer, body mass index, and smoking   8.5        \[[@B13]\]
  4          2011   Germany              Caucasian   678           669                  PB                  KASPar assays                          Age, sex, body mass index, and physical activity in METs                                6.5        \[[@B22]\]
  5          2014   China                Asian       1056          1056                 HB                  TaqMan                                 Age and gender                                                                          8          \[[@B4]\]
  6          2014   China                Asian       503           623                  HB                  TaqMan                                 Age and gender                                                                          8          \[[@B4]\]
  7          2014   Mexican              Mixed       99            144                  HB                  TaqMan                                 Age and marital status                                                                  6.5        \[[@B23]\]
  8          2015   China                Asian       1033          1147                 HB                  MALDI-TOF MS                           Age, sex, BMI, and family history of cancer                                             8          \[[@B24]\]

Abbreviations: HB, hospital based; KASPar assay, KBioscience's competitive allele-specific PCR amplification; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the Sequenom MassARRAY platform and iPLEX GOLD methodology; NM, not mentioned; PB, population based.

###### Genotype frequency distributions of PXR SNPs in included studies

  Ref. No.   Year   Cancer type         SNPs^1^            Sample size   Case   Control   *P*~HWE~   Included in meta-analysis                                   
  ---------- ------ ------------------- ------------------ ------------- ------ --------- ---------- --------------------------- ------ ------ ----- ----------- ---------
  1          2008   Breast cancer       rs3814055 (C/T)    62            300    36        23         3                           176    106    18    0.702       Yes
                    Breast cancer       rs1523127 (A/C)    62            300    36        24         2                           170    107    23    0.289       Yes
                    Breast cancer       rs2276706 (G/A)    62            300    37        23         2                           176    105    19    0.533       Yes
                    Breast cancer       rs3732358 (G/A)    62            300    62        0          0                           295    5      0     0.884       No^3^
                    Breast cancer       rs3732359 (A/G)    62            300    11        28         23                          101    125    74    **0.006**   No^2,3^
                    Breast cancer       rs3732360 (C/T)    62            300    11        28         23                          102    124    74    **0.004**   No^2,3^
                    Breast cancer       rs6438550 (A/G)    62            300    50        12         0                           216    76     8     0.674       No^3^
                    Breast cancer       rs3814057 (A/C)    59            300    18        27         14                          125    127    48    0.105       Yes
                    Breast cancer       rs3814058 (C/T)    59            300    18        27         14                          125    127    48    0.105       Yes
  2          2010   Breast cancer       rs6785049 (A/G)    2984          5318   1176      1382       426                         2036   2476   806   0.238       Yes
                    Breast cancer       rs10504191 (G/A)   2982          5315   2216      713        53                          3942   1260   113   0.297       Yes
  3          2011   Colorectal cancer   rs1523127 (A/C)    663           669    258       317        88                          245    326    98    0.534       Yes
                    Colorectal cancer   rs2276706 (G/A)    674           675    267       324        83                          251    329    95    0.438       Yes
                    Colorectal cancer   rs1464603 (A/G)    676           678    307       291        78                          303    310    65    0.263       Yes
                    Colorectal cancer   rs6785049 (A/G)    678           677    264       313        101                         260    323    94    0.692       Yes
                    Colorectal cancer   rs2276707 (C/T)    653           647    439       190        24                          446    180    21    0.588       Yes
                    Colorectal cancer   rs10504191 (G/A)   673           677    518       143        12                          499    161    17    0.356       Yes
                    Colorectal cancer   rs3814057 (A/C)    665           657    440       201        24                          458    177    22    0.341       Yes
  4          2011   Breast cancer       rs3814055 (C/T)    1020          1014   383       487        150                         384    497    133   0.159       Yes
                    Breast cancer       rs1523127 (A/C)    1020          1013   386       479        155                         390    483    140   0.623       Yes
                    Breast cancer       rs2276706 (G/A)    1020          1014   388       482        150                         400    485    129   0.336       Yes
                    Breast cancer       rs1464603 (A/G)    1019          1013   484       446        89                          467    451    95    0.352       Yes
                    Breast cancer       rs6785049 (A/G)    1020          1012   421       471        128                         391    486    135   0.406       Yes
                    Breast cancer       rs2276707 (C/T)    1018          1013   682       310        26                          690    292    31    0.987       Yes
                    Breast cancer       rs10504191 (G/A)   1020          1013   767       235        18                          754    239    20    0.835       Yes
                    Breast cancer       rs3814057 (A/C)    1020          1009   687       308        25                          703    277    29    0.786       Yes
  5          2014   Lung cancer         rs3814055 (C/T)    1056          1056   693       328        35                          706    316    34    0.851       Yes
                    Lung cancer         rs3732360 (C/T)    1056          1056   347       520        189                         346    533    177   0.242       Yes
                    Lung cancer         rs3814058 (C/T)    1056          1056   315       505        236                         365    491    200   0.128       Yes
  6          2014   Lung cancer         rs3814058 (C/T)    503           623    122       254        127                         185    303    135   0.600       Yes
  7          2014   Prostate cancer     rs2472677 (T/C)    99            144    40        43         16                          50     72     22    0.637       Noc
                    Prostate cancer     rs7643645 (G/A)    99            144    21        45         33                          26     75     43    0.499       Noc
  8          2015   Colorectal cancer   rs3732360 (C/T)    1033          1147   362       519        152                         434    560    153   0.189       Yes
                    Colorectal cancer   rs3814058 (C/T)    1033          1147   282       511        240                         421    561    165   0.318       Yes

Abbreviation: *P*~HWE~, the *P*-value for HWE in control groups. The results are in bold if *P*\<0.05.

^1^, The ancestral alleles were referenced in the NCBI database.

^2^, Excluded due to the SNP not being in accordance with HWE.

^3^, Excluded due to the limited number for this locus.

In general, obtained from eight eligible case--control studies, ten SNPs were involved in our final analysis including: rs10504191 G/A, rs3814058 C/T, rs6785049 A/G, rs1464603 A/G, rs1523127 A/C, rs2276706 G/A, rs2276707 C/T, rs3732360 C/T, rs3814055 C/T, rs3814057 A/C. Of these ten SNPs, the most prevalent one was rs3814058 with four articles encompassing 2651 cases and 3123 controls in Asian population. For rs10504191, rs6785049, rs1523127, rs2276706, rs3814055, and rs3814057 polymorphisms, three case--control studies were enrolled. Other polymorphisms were only investigated in two case--control studies.

Quantitative data synthesis of ten PXR SNPs {#sec3-2}
-------------------------------------------

We analyzed the associations between each *PXR* SNP and cancer risk, based on the whole population or two subgroup population stratified by ethnicity or cancer type, respectively. The stratified analyses were performed due to the existence of between-study heterogeneity. In whole population analyses, two (rs3814058 and rs3814057) of the ten SNPs were illustrated to be associated with cancer risk, while others did not show remarkable relations. Moreover, in subgroup analyses, seven SNPs (rs10504191, rs3814058, rs6785049, rs1523127, rs2276706, rs3814055 and rs3814057) were analyzed in 'cancer type' subgroup and four SNPs (rs1523127, rs2276706, rs3814055, and rs3814057) were analyzed in 'ethnicity' subgroup. However, only rs3814058 showed its association in lung cancer subgroup.

The PXR rs3814058 C/T polymorphism {#sec3-3}
----------------------------------

For rs3814058 C/T, its heterozygote genotype, homozygote variant genotype, dominant, recessive, and allelic models were all correlated with an elevated risk of cancer in Asian population (CT compared with CC: pooled OR = 1.280, 95%CI = 1.134--1.445, *P*=6.36E-05; TT compared with CC: pooled OR = 1.663, 95%CI = 1.268--2.182, *P*=2.40E-04 dominant model: pooled OR = 1.382, 95%CI = 1.233--1.549, *P*=2.58E-08; recessive model: pooled OR = 1.422, 95%CI = 1.132--1.786, *P*=0.002; T compared with C: pooled OR = 1.292, 95%CI = 1.140--1.465, *P*=6.35E-05). Moreover, the same effect could also be found in lung cancer subgroup analysis (CT compared with CC: OR = 1.271, 95%CI = 1.036--1.429, *P*=0.017; TT compared with CC: OR = 1.387, 95%CI = 1.141--1.687, *P*=0.001; dominant model: OR = 1.267, 95%CI = 1.089--1.473, *P*=0.002; recessive model: OR = 1.228, 95%CI = 1.038--1.452, *P*=0.017; T compared with C: OR = 1.186, 95%CI = 1.075--1.308, *P*=0.001, [Table 3](#T3){ref-type="table"}).

###### Meta-analysis of the association between PXR polymorphisms and cancer risk

  SNPs                   *n*   Heterozygote compared with homozygote wild   Homozygote variant compared with homozygote wild   Dominant model   Recessive model   Allelic model                                                                                                                                                    
  ---------------------- ----- -------------------------------------------- -------------------------------------------------- ---------------- ----------------- ---------------------- ------ -------------- ---------------------- ------ -------------- ---------------------- ------ ----------------- ---------------------- ------
  **rs10504191 (G/A)**   3     0.656                                        0.980 (0.897--1.071)                               0                0.157             0.820 (0.624--1.079)   0      0.441          0.967 (0.887--1.053)   0      0.166          0.825 (0.628--1.083)   0      0.277             0.958 (0.887--1.035)   0
  Cancer type                                                                                                                                                                                                                                                                                                                      
  Breast cancer          2     0.97                                         0.998 (0.909--1.097)                               0                0.259             0.844 (0.629--1.133)   0      0.757          0.986 (0.900--1.080)   0      0.259          0.845 (0.630--1.132)   0      0.549             0.975 (0.899--1.058)   0
  Colorectal cancer      1     0.234                                        0.856 (0.662--1.106)                               NA               0.313             0.680 (0.321--1.438)   NA     0.165          0.839 (0.655--1.075)   NA     0.359          0.705 (0.334--1.487)   NA     0.129             0.842 (0.674--1.051)   NA
  **rs3814058 (C/T)**    4     **6.36E-05**                                 1.280 (1.134--1.445)                               0                **2.40E-04^1^**   1.663 (1.268--2.182)   62.5   **2.58E-08**   1.382 (1.233--1.549)   4.1    **0.002^1^**   1.422 (1.132--1.786)   60.3   **6.35E-05^1^**   1.292 (1.140--1.465)   56.9
  Cancer type                                                                                                                                                                                                                                                                                                                      
  Lung cancer            2     **0.017**                                    1.271 (1.036--1.429)                               0                **0.001**         1.387 (1.141--1.687)   0      **0.002**      1.267 (1.089--1.473)   0      **0.017**      1.228 (1.038--1.452)   0      **0.001**         1.186 (1.075--1.308)   0
  Breast cancer          1     0.237                                        1.476 (0.774--2.815)                                                0.074             2.025 (0.934--4.391)   NA     0.112          1.627 (0.893--2.964)   NA     0.154          1.633 (0.832--3.207)   NA     0.055             1.476 (0.992--2.197)   NA
  Colorectal cancer      1     0.002                                        1.360 (1.122--1.649)                               NA               \<0.001           2.172 (1.693--2.786)   NA     \<0.001        1.544 (1.287--1.853)   NA     \<0.001        1.801 (1.447--2.243)   NA     \<0.001           1.452 (1.287--1.637)   NA
  **rs6785049 (A/G)**    3     0.235                                        0.952 (0.878--1.032)                               0                0.188             0.925 (0.825--1.039)   0      0.152          0.946 (0.876--1.021)   0      0.345          0.950 (0.854--1.057)   0      0.133             0.959 (0.908--1.013)   0
  Cancer type                                                                                                                                                                                                                                                                                                                      
  Breast cancer          2     0.262                                        0.952 (0.873--1.038)                               0                0.126             0.908 (0.803--1.027)   0      0.146          0.941 (0.867--1.021)   0      0.228          0.932 (0.832--1.045)   0      0.098             0.952 (0.898--1.009)   0
  Colorectal cancer      1     0.692                                        0.954 (0.757--1.203)                               NA               0.736             1.058 (0.762--1.470)   NA     0.84           0.978 (0.786--1.217)   NA     0.596          1.086 (0.801--1.471)   NA     0.898             1.010 (0.865--1.180)   NA
  **rs1464603 (A/G)**    2     0.418                                        0.943 (0.818--1.087)                               0                0.904             1.015 (0.799--1.288)   16.8   0.51           0.956 (0.835--1.094)   0      0.698          1.046 (0.833--1.314)   31.9   0.746             0.983 (0.888--1.089)   0
  **rs1523127 (A/C)**    3     0.731                                        0.975 (0.846--1.125)                               0                0.872             0.983 (0.800--1.209)   30.9   0.73           0.976 (0.853--1.118)   0      0.99           1.001 (0.827--1.211)   27.9   0.811             0.988 (0.898--1.088)   0
  Cancer type                                                                                                                                                                                                                                                                                                                      
  Breast cancer          2     0.935                                        1.008 (0.842--1.206)                               0                0.605             1.072 (0.825--1.393)   40.9   0.82           1.020 (0.860--1.209)   0      0.561          1.074 (0.844--1.368)   44.9   0.649             1.029 (0.911--1.162)   0
  Colorectal cancer      1     0.503                                        0.923 (0.731--1.166)                               NA               0.354             0.853 (0.609--1.194)   NA     0.388          0.907 (0.727--1.132)   NA     0.469          0.892 (0.654--1.216)   NA     0.33              0.925 (0.791--1.082)   NA
  Ethnicity                                                                                                                                                                                                                                                                                                                        
  Caucasian              2     0.685                                        0.970 (0.838--1.124)                               0                0.951             1.007 (0.816--1.241)   34.5   0.76           0.979 (0.851--1.125)   0      0.812          1.024 (0.844--1.242)   19.5   0.925             0.995 (0.902--1.098)   27.8
  Asian                  1     0.843                                        1.059 (0.599--1.874)                               0                0.241             0.411 (0.093--1.820)   NA     0.84           0.944 (0.543--1.643)   NA     0.224          0.401 (0.092--1.749)   NA     0.495             0.852 (0.538--1.349)   NA
                                                                                                                                                                                                                                                                                                                                   
  **rs2276706 (G/A)**    3     0.859                                        0.987 (0.857--1.137)                               0                0.888             1.015 (0.823--1.253)   46.7   0.915          0.993 (0.868--1.135)   20.7   0.799          1.026 (0.844--1.246)   41     0.96              1.002 (0.910--1.104)   27.3
  Cancer type                                                                                                                                                                                                                                                                                                                      
  Breast cancer          2     0.777                                        1.026 (0.858--1.227)                               0                0.286             1.157 (0.885--1.511)   20.8   0.565          1.051 (0.887--1.246)   0      0.283          1.146 (0.894--1.468)   23.2   0.344             1.061 (0.939--1.199)   0
  Colorectal cancer      1     0.512                                        0.926 (0.735--1.166)                               NA               0.258             0.821 (0.584--1.155)   NA     0.359          0.902 (0.725--1.124)   NA     0.34           0.857 (0.625--1.176)   NA     0.261             0.914 (0.782--1.069)   NA
  Ethnicity                                                                                                                                                                                                                                                                                                                        
  Caucasian              2     0.827                                        0.984 (0.850--1.138)                               0                0.972^1^          1.007 (0.696--1.456)   65.2   0.942          0.995 (0.866--1.143)   0      0.893^1^       1.022 (0.746--1.399)   58.8   0.981^1^          0.998 (0.852--1.169)   59.8
  Asian                  1     0.888                                        1.042 (0.587--1.849)                               NA               0.366             0.501 (0.112--2.243)   NA     0.883          0.959 (0.549--1.674)   NA     0.35           0.493 (0.112--2.173)   NA     0.623             0.890 (0.558--1.418)   NA
  **rs2276707 (C/T)**    2     0.356                                        1.073 (0.924--1.248)                               0                0.896             0.974 (0.655--1.449)   0      0.405          1.064 (0.920--1.230)   0      0.813          0.954 (0.643--1.415)   0      0.518             1.042 (0.919--1.182)   0
  **rs3732360 (C/T)**    2     0.537                                        1.043 (0.913--1.190)                               0                0.212             1.123 (0.936--1.349)   0      0.346          1.062 (0.937--1.205)   0      0.257          1.100 (0.933--1.298)   0      0.215             1.056 (0.969--1.151)   0
  **rs3814055 (C/T)**    3     0.745                                        1.022 (0.898--1.163)                               0                0.431             1.098 (0.870--1.387)   0      0.593          1.034 (0.914--1.171)   0      0.373          1.105 (0.888--1.375)   0      0.421             1.040 (0.945--1.145)   0
  Ethnicity                                                                                                                                                                                                                                                                                                                        
  Asian                  2     0.535                                        1.058 (0.886--1.263)                               0                0.951             1.014 (0.647--1.590)   0      0.551          1.054 (0.887--1.251)   0      0.982          0.995 (0.637--1.554)   0      0.615             1.038 (0.897--1.203)   0
  Caucasian              1     0.854                                        0.982 (0.813--1.187)                               NA               0.378             1.131 (0.861--1.486)   NA     0.881          1.014 (0.847--1.213)   NA     0.301          1.142 (0.888--1.469)   NA     0.531             1.041 (0.918--1.182)   NA
  Cancer type                                                                                                                                                                                                                                                                                                                      
  Breast cancer          2     0.91                                         0.990 (0.827--1.184)                               0                0.428             1.114 (0.853--1.453)   0      0.866          1.015 (0.856--1.204)   0      0.348          1.125 (0.880--1.439)   0      0.557             1.037 (0.918--1.172)   0
  Lung cancer            1     0.558                                        1.057 (0.877--1.274)                               NA               0.847             1.049 (0.647--1.701)   NA     0.55           1.057 (0.882--1.265)   NA     0.903          1.030 (0.638--1.665)   NA     0.579             1.045 (0.895--1.220)   NA
  **rs3814057 (A/C)**    3     **0.036**                                    1.170 (1.010--1.355)                               0                0.457             1.145 (0.802--1.634)   32.6   **0.037**      1.162 (1.009--1.339)   0      0.656          1.082 (0.766--1.527)   9.1    0.053             1.127 (0.999--1.271)   8
  Ethnicity                                                                                                                                                                                                                                                                                                                        
  Caucasian              2     0.061                                        1.155 (0.993--1.343)                               0                0.961             0.990 (0.663--1.478)   0      0.081          1.138 (0.984--1.317)   0      0.795          0.948 (0.637--1.412)   0      0.152             1.097 (0.966--1.245)   0
  Asian                  1     0.237                                        1.476 (0.774--2.815)                               NA               0.074             2.025 (0.934--4.391)   NA     0.112          1.627 (0.893--2.964)   NA     0.154          1.633 (0.832--3.207)   NA     0.055             1.476 (0.992--2.197)   NA
  Cancer type                                                                                                                                                                                                                                                                                                                      
  Breast cancer          2     0.11                                         1.163 (0.966--1.399)                               0                0.556^1^          1.275 (0.567--2.865)   66.3   0.117          1.154 (0.965--1.379)   28.5   0.687^1^       1.141 (0.602--2.160)   54.5   0.25^1^           1.191 (0.884--1.605)   53.6
  Colorectal cancer      1     0.173                                        1.182 (0.929--1.504)                               NA               0.674             1.136 (0.627--2.055)   NA     0.167          1.177 (0.934--1.483)   NA     0.796          1.081 (0.600--1.947)   NA     0.201             1.139 (0.933--1.391)   NA

^1^, *P* was calculated by random model. The results are in bold if *P*\<0.05.

The PXR rs3814057 A/C polymorphism {#sec3-4}
----------------------------------

For rs3814057 A/C, its heterozygote genotype and dominant models were found to be correlated with an increased cancer risk in whole population (AC compared with AA: pooled OR = 1.170, 95%CI = 1.010--1.355, *P*=0.036; dominant model: pooled OR = 1.162, 95%CI = 1.009--1.339, *P*=0.037, [Table 3](#T3){ref-type="table"}). No association of rs3814057 was found in other genetic models or any subgroups analysis ([Table 3](#T3){ref-type="table"}).

Sensitivity analysis {#sec3-5}
--------------------

Sensitivity analyses were performed to investigate the influence of individual study on the pooled findings by calculating the sensitivity before and after excluding each study from the meta-analysis (Supplementary Table S1). For rs3814057, it was no longer significant after the removal of each study individually (Supplementary Table S1).

Publication bias {#sec3-6}
----------------

Begg's tests and Egger's tests were used to calculate the potential publication bias. Evaluation of publication bias for all meta-analyses revealed that the publication biases were observed in rs3814055 (the variant genotype and the recessive model) and in rs3814057 (all models), for *P*\<0.1 in Egger's tests ([Table 4](#T4){ref-type="table"}). This may be caused by language bias, the insufficiency publications with adverse results and/or the elevated estimates due to a deficient methodological design for small studies \[[@B25]\].

###### The results of Begg's and Egger's tests for the publication bias

  Comparison type                                    Begg's test   Egger's test             
  -------------------------------------------------- ------------- -------------- --------- -----------
  **rs10504191 (G/A)**                                                                      
  Heterozygote compared with homozygote wild         −1.570        0.117          −2.130    0.279
  Homozygote variant compared with homozygote wild   −0.520        0.602          −0.550    0.682
  Dominant model                                     −1.570        0.117          −1.800    0.323
  Recessive model                                    −0.520        0.602          −0.420    0.749
  Allelic model                                      −1.570        0.117          −1.530    0.368
  **rs3814058 (C/T)**                                                                       
  Heterozygote compared with homozygote wild         0.000         1.000          0.570     0.629
  Homozygote variant compared with homozygote wild   0.680         0.497          0.120     0.912
  Dominant model                                     0.000         1.000          0.300     0.795
  Recessive model                                    0.680         0.497          0.070     0.949
  Allelic model                                      0.000         1.000          0.150     0.893
  **rs6785049 (A/G)**                                                                       
  Heterozygote compared with homozygote wild         −0.520        0.602          −0.860    0.549
  Homozygote variant compared with homozygote wild   0.520         0.602          0.580     0.667
  Dominant model                                     −0.520        0.602          −0.270    0.832
  Recessive model                                    1.570         0.117          1.020     0.495
  Allelic model                                      0.520         0.602          0.280     0.829
  **rs1464603 (A/G)**                                                                       
  Heterozygote compared with homozygote wild         −1.000        0.317          NA        NA
  Homozygote variant compared with homozygote wild   1.000         0.317          NA        NA
  Dominant model                                     1.000         0.317          NA        NA
  Recessive model                                    1.000         0.317          NA        NA
  Allelic model                                      1.000         0.317          NA        NA
  **rs1523127 (A/C)**                                                                       
  Heterozygote compared with homozygote wild         −0.520        0.602          0.270     0.830
  Homozygote variant compared with homozygote wild   −1.570        0.117          −1.410    0.392
  Dominant model                                     −0.520        0.602          −0.390    0.761
  Recessive model                                    −1.570        0.117          −1.670    0.343
  Allelic model                                      −0.520        0.602          −0.870    0.543
  **rs2276706 (G/A)**                                                                       
  Heterozygote compared with homozygote wild         −0.520        0.602          0.050     0.967
  Homozygote variant compared with homozygote wild   −0.520        0.602          −0.840    0.556
  Dominant model                                     −0.520        0.602          −0.350    0.785
  Recessive model                                    −0.520        0.602          −0.940    0.521
  Allelic model                                      −0.520        0.602          −0.580    0.668
  **rs2276707 (C/T)**                                                                       
  Heterozygote compared with homozygote wild         −1.000        0.317          NA        NA
  Homozygote variant compared with homozygote wild   1.000         0.317          NA        NA
  Dominant model                                     1.000         0.317          NA        NA
  Recessive model                                    1.000         0.317          NA        NA
  Allelic model                                      1.000         0.317          NA        NA
  **rs3732360 (C/T)**                                                                       
  Heterozygote compared with homozygote wild         −1.000        0.317          NA        NA
  Homozygote variant compared with homozygote wild   1.000         0.317          NA        NA
  Dominant model                                     −1.000        0.317          NA        NA
  Recessive model                                    1.000         0.317          NA        NA
  Allelic model                                      −1.000        0.317          NA        NA
  **rs3814055 (C/T)**                                                                       
  Heterozygote compared with homozygote wild         −0.520        0.602          0.230     0.857
  Homozygote variant compared with homozygote wild   −1.570        0.117          −25.410   **0.025**
  Dominant model                                     0.520         0.602          −0.100    0.939
  Recessive model                                    −1.570        0.117          −9.210    **0.069**
  Allelic model                                      −0.520        0.602          −2.770    0.220
  **rs3814057 (A/C)**                                                                       
  Heterozygote compared with homozygote wild         1.570         0.117          10.860    **0.058**
  Homozygote variant compared with homozygote wild   1.570         0.117          8.400     **0.075**
  Dominant model                                     1.570         0.117          11.800    **0.054**
  Recessive model                                    1.570         0.117          52.120    **0.012**
  Allelic model                                      1.570         0.117          13.760    **0.046**

Abbreviation: NA, not available. The results are in bold if *P*\<0.1.

TSA and FPRP analyses {#sec3-7}
---------------------

To prevent random errors and intensify the reliability of our conclusions, we conducted TSA. Regarding the rs3814058 SNP, its TSA analysis elucidated that the cumulative evidence for rs3814058 SNP is adequate and no further trials are needed to reinforce our conclusions ([Figure 2](#F2){ref-type="fig"}). For other SNPs, however, TSA analysis showed that there was no sufficient cumulative evidence to strengthen the robustness of our findings (figures were not shown).

![The required information size to demonstrate the relevance of *PXR* rs3814058 SNP with cancer risk\
The blue line is the cumulative Z-curve. The red inward-sloping line represents the trial sequential monitoring boundaries.](bsr-38-bsr20171614-g2){#F2}

Finally, we computed the FPRP values for significant findings. With the assumption of prior probability 0.1, the FPRP values (for all genotype models in overall cancer analysis and the heterozygote genotype, homozygote variant genotype and dominant models in lung cancer subgroup analysis) of rs3814058 SNP were \<0.20, implying that these significant correlations were noteworthy ([Table 5](#T5){ref-type="table"}). On the contrary, none of the FPRP values of rs3814057 SNP were \<0.20 ([Table 5](#T5){ref-type="table"}).

###### FPRP values for correlations between genotype frequency of PXR and cancer risk

  Genotype                     OR (95%CI)             *P*-value   Statistical power^1^   Prior probability^3^                                       
  ---------------------------- ---------------------- ----------- ---------------------- ---------------------- ----------- ----------- ----------- -----------
  **rs3814058 (C/T)**                                                                                                                               
    CT compared with CC        1.280 (1.134--1.445)   6.36E-05    0.599                  **0.000**              **0.001**   **0.010**   0.096       0.515
    TT compared with CC        1.674 (1.262--2.219)   3.45E-04    1.000                  **0.001**              **0.003**   **0.033**   0.256       0.775
    CT + TT compared with CC   1.382 (1.233--1.549)   2.58E-08    0.319                  **0.000**              **0.000**   **0.000**   **0.000**   **0.001**
    TT compared with CT + CC   1.422 (1.132--1.786)   0.002       0.974                  **0.006**              **0.018**   **0.169**   0.672       0.954
    T compared with C          1.292 (1.140--1.465)   6.35E-05    0.657                  **0.000**              **0.001**   **0.009**   **0.088**   0.491
  Subgroup (lung cancer)                                                                                                                            
    CT compared with CC        1.271 (1.036--1.429)   0.017       0.802                  **0.060**              **0.160**   0.677       0.955       0.995
    TT compared with CC        1.387 (1.141--1.687)   0.001       0.480                  **0.006**              **0.018**   **0.171**   0.676       0.954
    CT + TT compared with CC   1.267 (1.089--1.473)   0.002       0.223                  **0.026**              **0.075**   0.470       0.900       0.989
    TT compared with CT + CC   1.228 (1.038--1.452)   0.017       0.173                  0.228                  0.470       0.907       0.990       0.999
    T compared with C          1.186 (1.075--1.308)   0.001       0.000^2^               0.968                  0.989       0.999       1.000       1.000
  **rs3814057 (A/C)**                                                                                                                               
    AC compared with AA        1.170 (1.010--1.355)   0.036       0.297                  0.267                  0.522       0.923       0.992       0.999
    AC + CC compared with AA   1.162 (1.009--1.339)   0.037       0.300                  0.270                  0.526       0.924       0.992       0.999

^1^, Statistical power was computed using the sample size of case and control, OR and *P-*values.

^2^, When the statistical power\<0.0001, we regarded it as 0.0001.

^3^, The FPRP are in bold if the values are \<0.2.

Discussion {#sec4}
==========

Through numerous mechanisms, *PXR* have been revealed to regulate cell proliferation in a plenty of cancers, including colon, liver, breast, prostate, ovarian, and so on \[[@B26]\]. It is widely accepted that the polymorphisms of *PXR* might be correlated to the predisposition to cancer by influencing its expression and/or its function. In the present study, we gathered all related case--control studies and available data, presenting the first systematic review and meta-analysis for the association between ten prevalently studied SNPs in *PXR* and the susceptibility to overall cancer. Of these ten SNPs, two (rs3814058 C/T and rs3814057 A/C) were demonstrated to be associated with an elevated risk of cancer. No correlations were identified amongst other SNPs.

Our study have generalized the current status of the studies on cancer associated SNPs in *PXR*. In order to reinforce our conclusions, we performed the TSA and FPRP analysis, which could minimize the errors and guide future researchers to decide whether to continue focussing on this topic. What is more, we provided clues for researchers to figure out the complicated mechanisms of cancer development and screen novel functional genetic biomarkers for cancer prediction.

For rs3814058 C/T polymorphism, our study elucidated that it was statistically associated with overall cancer risk in every genotype model and it could also reach the significance in lung cancer subgroup and the significant associations were confirmed by TSA and FPRP. The meta-analysis of rs3814058 covered four case--control studies and three of them reported the same findings with us. Edwin Sandanaraj's research on breast cancer, however, holds a different attitude. To explain the discrepancy, we observed that the expression of *PXR* was depressed or lost in CRC and lung cancer, however elevated in breast cancer. \[[@B3],[@B26]\]. Most likely, this tissue specificity can explain the unconformity of the results and more stratification analysis of cancer type ought to be done for rs3814058 polymorphism. Located in the 3′-UTR region of *PXR*, the C to T transition of rs3814058 obtained a novel miRNA (hsa-*miR-129-5p*) binding site which was identified by bioinformatics analysis, leading to a depression of *PXR* expression level in CRC and lung cancer \[[@B4],[@B24]\]. This could reasonably explain the association between the rs3814058 polymorphism and the increment of cancer susceptibility. Therefore, further researchers should pay more attention to the role of rs3814058 on cancerogenesis.

Regarding rs3814057 A/C polymorphism, our results conflicted with other involved studies to some extent. We revealed that the heterozygote genotype and the dominant models of rs3814057 could elevate the risk of overall cancer, which provided a feasible biomarker for cancer prediction. The meta-analysis of rs3814057 involved three case--control studies. None of them were reported to be associated with cancer risk. Based on the TSA, we noticed that the cumulative evidence of rs3814057 was not adequate enough to obtain a reliable conclusion. Likewise, rs3814057 polymorphism was located in 3′-UTR region of *PXR*, putatively binding to several miRNAs, which was speculated by bioinformatics website '<https://snpinfo.niehs.nih.gov/>'. Thus, the rs3814057 polymorphism might influence the expression of *PXR* gene and boost the tumor progression. The unfortunate reality is that no studies have focussed on the mechanisms of rs3814057 polymorphism thus far. As a consequence, association studies and mechanism studies concentrated on rs3814057 are extremely needed to further confirm its role on cancer prediction.

Limitations in our study must be recognized. First, articles in English rather than in other languages were selected, which might result in publication bias. Second, studies of *PXR* polymorphisms on cancer susceptibility field remains emerging, so that the relevant investigations are limited. Last but not least, though *PXR* gene can influence the development of a variety of cancers, its mechanisms in different cancers have been proved to be distinct \[[@B26]\]. Hence, the tissue specificity must be well recognized in the future studies and meta-analyses of *PXR* polymorphisms focussed on only one cancer are in demand.

In conclusion, we systematically reviewed the association between *PXR* polymorphisms and risk of overall cancer. All available data was obtained to conduct a meta-analysis for ten prevalent SNPs. Two of them (rs3814058 C/T and rs3814057 A/C) were elucidated to be correlated with cancer risk in the whole population or some subgroups. Our study generalized the current status of the studies on cancer associated SNPs in *PXR* gene, providing novel clues for further investigators to identify more biomarkers with cancer-forewarning function.
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PXR
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